ATLASVertex Pharmaceuticals (VRTX) Q3 2026 earnings results
Vertex Pharmaceuticals (VRTX) reported EPS of $4.76 against an analyst estimate of $4.75: in line with the estimate (+$0.01 (0.2%)). The quarter ended Sep 30, 2026; the company reported on Monday, November 2, 2026, after the close.
Status: Confirmed · 16:43 ET, Nov 2 · Source: EODHD (calendar and fundamentals, cross-checked)
Notify me when Vertex Pharmaceuticals reports
Track VRTX free Add Vertex Pharmaceuticals to a free ATLAS watchlist.
VRTX Q3 2026 results at a glance
| EPS reported | $4.76 |
|---|---|
| EPS estimate | $4.75 |
| Surprise | In line · +$0.01 (+0.2%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 2, 2026, after the close |
| Status | Confirmed · 16:43 ET, Nov 2 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Vertex Pharmaceuticals’s Q3 2026, a calendar-year company.
Vertex Pharmaceuticals EPS surprise history: last 3 quarters
Vertex Pharmaceuticals beat the EPS estimate in 1 of its last 3 reports, with an average surprise of +2.2%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 2, 2026 | $4.75 | $4.76 | +0.2% | In line | – |
| Aug 3, 2026 | $4.75 | $4.73 | -0.4% | In line | +0.3% |
| May 6, 2026 | $2.55 | $2.72 | +6.7% | Beat | +0.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
VRTX stock reaction to the report
The price reaction will be added after the Nov 3, 2026 close.
This section appears once a post-report closing price exists and updates with every new close.
Next VRTX earnings report
Vertex Pharmaceuticals has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the VRTX earnings calendar.
ATLAS fair value and signal for VRTX
| Last price | $554.61 (-0.8%) |
|---|---|
| ATLAS fair value | $342.16 (range $235.66–$414.19) · price is 62% above it |
| Chance of a higher close in 1 month | 51% (normal range $528.17–$584.91) |
These are model outputs from the same valuation and calibrated model as the Vertex Pharmaceuticals stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Vertex Pharmaceuticals Q3 2026 earnings: frequently asked questions
Did Vertex Pharmaceuticals beat earnings estimates for Q3 2026?
Vertex Pharmaceuticals reported EPS of $4.76 against an analyst estimate of $4.75: in line with the estimate (+$0.01 (0.2%)).
When did Vertex Pharmaceuticals report Q3 2026 results?
Vertex Pharmaceuticals reported on Monday, November 2, 2026, after the close, for the quarter ended Wednesday, September 30, 2026.
How often does VRTX beat EPS estimates?
In its last 3 reports with a recorded result, Vertex Pharmaceuticals beat the EPS estimate 1 times; the average surprise was +2.2%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer